NCT06586242View on ClinicalTrials.gov

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2036

Conditions
Esophageal Cancer
Interventions
DRUG

Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin

200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w

Trial Locations (1)

710000

RECRUITING

The First Affiliated Hospital of the Air Force Medical University, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER